Search results for: ayvakit

30 06, 2020

Blueprint Medicines Announces Publication in The Lancet Oncology

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

15 05, 2020

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

By |2020-05-15T10:10:47-04:00May 15th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.

30 04, 2020

Blueprint Medicines Presents Cost of Testing Poster

By |2020-04-30T14:50:52-04:00April 30th, 2020|Mutational Testing, News, Patient Support|

Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.

28 04, 2020

Hope & Obstacles Along a GIST Journey

By |2020-04-28T15:10:16-04:00April 28th, 2020|Member Stories, News, Newsletter|

Many GIST patients around the world struggle with getting the treatment they need to survive and thrive. Arun Krishnan’s story illustrates how collaboration between patient groups and doctors across the globe can affect patient survival.

9 01, 2020

Breaking News for GIST Patients – Avapritinib Approved!

By |2020-01-10T16:06:14-05:00January 9th, 2020|News|

Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top